JP2018511628A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511628A5
JP2018511628A5 JP2017553879A JP2017553879A JP2018511628A5 JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5 JP 2017553879 A JP2017553879 A JP 2017553879A JP 2017553879 A JP2017553879 A JP 2017553879A JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5
Authority
JP
Japan
Prior art keywords
seq
group
alkyl
formula
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511628A (ja
Filing date
Publication date
Priority claimed from GBGB1506393.6A external-priority patent/GB201506393D0/en
Application filed filed Critical
Publication of JP2018511628A publication Critical patent/JP2018511628A/ja
Publication of JP2018511628A5 publication Critical patent/JP2018511628A5/ja
Pending legal-status Critical Current

Links

JP2017553879A 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体 Pending JP2018511628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506393.6 2015-04-15
GBGB1506393.6A GB201506393D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
PCT/EP2016/058371 WO2016166299A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2018511628A JP2018511628A (ja) 2018-04-26
JP2018511628A5 true JP2018511628A5 (enExample) 2019-05-09

Family

ID=53333825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553879A Pending JP2018511628A (ja) 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体

Country Status (11)

Country Link
US (1) US20180125994A1 (enExample)
EP (1) EP3283118A1 (enExample)
JP (1) JP2018511628A (enExample)
KR (1) KR20170137115A (enExample)
CN (1) CN107683146A (enExample)
AU (1) AU2016249877A1 (enExample)
BR (1) BR112017022256A2 (enExample)
CA (1) CA2981920A1 (enExample)
GB (1) GB201506393D0 (enExample)
MX (1) MX2017013154A (enExample)
WO (1) WO2016166299A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6704532B1 (ja) 2017-02-08 2020-06-03 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SI3544636T1 (sl) 2017-02-08 2021-08-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
HRP20221063T1 (hr) 2017-04-18 2022-11-11 Medimmune Limited Konjugati pirolobenzodiazepina
US11596696B2 (en) 2017-04-20 2023-03-07 Adc Therapeutics Sa Combination therapy with an anti-CD25 antibody-drug conjugate
EP3612235A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy with an anti-psma antibody-drug conjugate
US11426467B2 (en) 2017-06-14 2022-08-30 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD25 ADC
JP7220203B2 (ja) 2017-08-18 2023-02-09 メドイミューン・リミテッド ピロロベンゾジアゼピン複合体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
JP7210770B2 (ja) * 2019-03-29 2023-01-23 メドイミューン・リミテッド 化合物及びその複合体
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
KR20240049342A (ko) * 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
CN116370651A (zh) * 2023-04-04 2023-07-04 上海愿智生物技术有限公司 一种抗psma抗体-药物缀合物及其制备方法和应用
WO2025145034A1 (en) * 2023-12-29 2025-07-03 T.O.A.D. Oncology Sa Anti-psma conjugates and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908226A (pt) * 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
WO2006065533A2 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2011108714A1 (ja) * 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
EP2638066A4 (en) * 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
PT2906253T (pt) * 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
ES2680153T3 (es) * 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
MX2016002545A (es) * 2013-08-28 2016-06-17 Stemcentrx Inc Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso.

Similar Documents

Publication Publication Date Title
JP2018511628A5 (enExample)
JP2018516243A5 (enExample)
JP2018502902A5 (enExample)
JP2020506951A5 (enExample)
JP2020531471A5 (enExample)
JP2016508130A5 (enExample)
RU2019122802A (ru) Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
JP2018516860A5 (enExample)
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
JP2020514419A5 (enExample)
JP2014527974A5 (enExample)
JP2016505586A5 (enExample)
JP2014528466A5 (enExample)
JP2020524174A5 (enExample)
JP2014528467A5 (enExample)
JP2018070648A5 (enExample)
JP2017518040A5 (enExample)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2013505946A5 (enExample)
JP2016531915A5 (enExample)
JP2017506234A5 (enExample)
JP2020519643A5 (enExample)
JP2017528467A5 (enExample)
JP2021506788A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat